We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toSession-7-Track-3-Policy-Updates-The-Evolution-of-Customer-Facing-Medical-Roles

Medical Affairs and Scientific Communications Forum

Medical Communication, MSL, and Medical Writing.

Session 7 Track 3: Policy Updates: The Evolution of Customer-Facing Medical Roles

    Session Chair(s)
      Kathryn  Bucci, PharmD

      Kathryn Bucci, PharmD

      • Medical Governance Lead
      • Pfizer, Inc., United States
      Ed  Cunningham, PharmD

      Ed Cunningham, PharmD

      • Senior Director, Neurology Medical Science Liaison Team Lead
      • Sunovion Pharmaceuticals, Inc., United States
    Recent court rulings and environmental trends are shaping what pharma can communicate about their products. The current FDA rules pose challenges and the need for clarification as companies work to interpret these rules. As the demand for medical information continues to increase, this session will discuss how the interpretation and application of these rules is expected to further evolve the role of customer-facing medical teams.
    Learning Objective : At the conclusion of this session, participants should be able to:
    • Prepare an overview of recent court rulings regarding manufacturers’ ability to communicate
    • Describe the current challenges in FDA rules and how they influence pharma companies
    • Explain how companies are interpreting and applying the rules to customer-facing medical roles
    • Describe what the industry can do to advance capabilities and move field-based medical roles forward
      Michelle  Drozd


      Michelle Drozd

      • Deputy Vice President, Policy & Research
      • Pharmaceutical Research and Manufacturers of America (PhRMA), United States
      Michael S. Labson, JD


      Michael S. Labson, JD

      • Partner
      • Covington & Burling LLP, United States